RAD-140 (Testolone)
PerformancePhase 1Also known as: Testolone, RAD140, RAD 140, Vosilasarm, Testalone
RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer.
Overview
At A Glance
RAD-140 is a nonsteroidal agonist of the androgen receptor built on a 1,3,4-oxadiazole scaffold (PMID: 24900290). It binds the receptor and drives transcription of androgen-responsive genes, producing anabolic effects in muscle in rats (PMID: 40680216) and neuroprotective effects…
Overview
RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
1182367-47-0
Molecular Formula
C20H16ClN5O2
Molecular Mass
393.83 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Mechanism-based: contraindicated in pregnancy, since androgen receptor agonists can virilize a female fetus, and in men with known or suspected prostate cancer. Pre-existing liver disease or raised transaminases is both mechanism-based and case-report-based, given how frequently transaminase and bilirubin rises appeared in the phase 1 trial and in published liver injury reports (PMID: 34565686, PMID: 36945289). Cardiac case reports, including one in a 16-year-old, are a reason to avoid it in anyone with known cardiac disease (PMID: 39157568, PMID: 38864168). Prohibited in tested sport at all times (PMID: 28137616).
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$84.99
—
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
RAD-140 capsules (60) | capsule | 60 capsules● In Stock | $84.99BEST | — | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling RAD-140 (Testolone)
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllITPP
PerformancePreclinicalITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
LGD-4033 (Ligandrol)
PerformancePhase 2LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).
Ostarine (Enobosarm, MK-2866)
PerformancePhase 3Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.
PEG-MGF
PerformancePreclinicalPEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.
SLU-PP-332
PerformancePreclinicalSLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism.
YK-11
PerformancePreclinicalYK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them.
View Full Dosage Guide →
Protocols, calculator & safety for RAD-140 (Testolone)
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686)
Molecular Weight
393.83 g/mol
Administration
Oral
CAS Number
1182367-47-0
Trial Phase
Phase 1
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is RAD-140 (Testolone) used for in research?
RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator.
The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686).
Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703).
The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168).
RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).
What forms does RAD-140 (Testolone) come in?
RAD-140 (Testolone) is available in capsule form.
How much does RAD-140 (Testolone) cost?
Prices start at $84.99 across 1 verified vendor.
How do I compare RAD-140 (Testolone) vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View AllITPP
PerformancePreclinicalITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
LGD-4033 (Ligandrol)
PerformancePhase 2LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).
Ostarine (Enobosarm, MK-2866)
PerformancePhase 3Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.
PEG-MGF
PerformancePreclinicalPEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.
SLU-PP-332
PerformancePreclinicalSLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism.
YK-11
PerformancePreclinicalYK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.